Close Menu

NEW YORK – Co-Diagnostics said last week that it has been notified by Nasdaq that it failed to meet a listing requirement and may face delisting action.

In a document filed with the US Securities and Exchange Commission, the Salt Lake City-based diagnostics firm said that it received a letter on July 2 from Nasdaq informing it that its stock had closed below the minimum $1 per share requirement for 30 consecutive days. Co-Diagnostics has 180 calendar days, or until Dec. 30, to regain compliance by having its stock close at $1 or more per share for 10 consecutive days.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.